Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells.
about
Trial watch - inhibiting PARP enzymes for anticancer therapyTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyAutophagy, autophagy-associated adaptive immune responses and its role in hematologic malignanciesTrial Watch: Proteasomal inhibitors for anticancer therapySynthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress.Combinatorial strategies for the induction of immunogenic cell death.The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cellsZn(II)-curc targets p53 in thyroid cancer cellsA fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma.Hyperglycemia triggers HIPK2 protein degradation.Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer.Effects of non-toxic zinc exposure on human epidermal keratinocytes.p53-Dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditionsZinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.Consensus guidelines for the detection of immunogenic cell death.Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice.
P2860
Q26745673-1FDB0597-E8AB-40D4-9355-F5CF6CF4150EQ27004011-4EE12326-1AA6-45AA-8EE9-9FD90C136693Q28072922-F3A6C0EB-9B99-457E-82CB-7F55EA79B3A4Q28082910-76B26A25-A21E-46C0-9192-33D649C2B630Q33776397-4319AE0D-D2B3-416D-A21C-3630C9749B52Q35535140-0C40FBCB-5117-43E5-B6A2-42010E6FB602Q35986990-2987E303-B50C-454D-83E9-64AC4289F6DDQ36094135-3B0162A9-AB48-4776-BEFF-C4C920754B4DQ37364980-38A7AD1C-223E-4116-B5CE-6B017D666EE2Q37482664-E889DB38-0D95-456D-BC65-DDEFD7BDD38BQ37702069-122957EA-E84C-4D78-93FC-E0BD4967B6A0Q38845614-601F1EFE-6A2D-49CA-866C-89779B1518BDQ38912188-FB118ADD-2753-42C2-A4C9-BBA6A962579EQ41279239-574418FE-AEF7-48C5-BAC4-798E336124C0Q42317473-79C009F0-B66C-463E-9454-0AA4C80DB4E3Q42553556-981DB234-40DB-4E61-918D-F6BF86583D6FQ51783558-636246BA-5A22-4FE0-9AC4-F455BE8C943C
P2860
Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Zinc supplementation is requir ...... -functionally deficient cells.
@en
Zinc supplementation is requir ...... -functionally deficient cells.
@nl
type
label
Zinc supplementation is requir ...... -functionally deficient cells.
@en
Zinc supplementation is requir ...... -functionally deficient cells.
@nl
prefLabel
Zinc supplementation is requir ...... -functionally deficient cells.
@en
Zinc supplementation is requir ...... -functionally deficient cells.
@nl
P2093
P2860
P356
P1433
P1476
Zinc supplementation is requir ...... -functionally deficient cells.
@en
P2093
Alberto Faggioni
Alessia Garufi
Livia Di Renzo
Mara Cirone
Marisa Granato
P2860
P304
P356
10.4161/ONCI.26198
P50
P577
2013-09-12T00:00:00Z